Medicare can pay for obesity drugs like Wegovy in certain heart patients
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles
Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
Jessica Biel unveiled a dramatic hair transformation - from chest-length locks to a short bob - on S2024-05-21Advisory: Schedules for China's two sessions on March 4
(Xinhua) 08:24, March 04, 2024BEIJING, March 3 (Xinhua) -- The following are the schedules for the s2024-05-21Xi's Shanghai inspection tour sends signal of high
(Xinhua) 10:44, December 02, 2023BEIJING, Dec. 1 (Xinhua) -- Chinese President Xi Jinping's recent i2024-05-21Chinese premier stresses development of water conservancy, high
(Xinhua) 00:17, November 18, 2023BEIJING, Nov. 17 (Xinhua) -- Chinese Premier Li Qiang has called fo2024-05-21I was 'brokefished' by my friend for £400
I need your help. My friend K has been recently telling our friendship group about how dire his fina2024-05-21Xi extends New Year wishes to all
(Xinhua) 19:05, December 31, 2023BEIJING, Dec. 31 (Xinhua) -- Chinese President Xi Jinping on Sunday2024-05-21
atest comment